Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03240211 · ClinicalTrials.gov registry record · Phase 1
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
A Phase 1 study of CTCL and PTCL, sponsored by University of Virginia.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 2
- Study locations
NCT03240211 is a Phase 1 study of CTCL and PTCL that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 37 participants, below the 67-participant average among 4 other CTCL trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03240211, a Phase 1 study of CTCL and PTCL, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
Interventions
- DRUG Pembrolizumab
- DRUG Decitabine
- DRUG Pralatrexate
Study Locations (2)
Pennsylvania
- Allegheny Health Network - Pittsburgh
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2026-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03240211
The ClinicalTrials.gov registry entry for NCT03240211 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 4 other CTCL trials with a reported enrollment target (45% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with CTCL appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03240211 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT03240211 about?
NCT03240211 is a clinical study titled "Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL". This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at t...
What is the current status of trial NCT03240211?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2022-02-02. Estimated completion is 2026-05-25.
What conditions does trial NCT03240211 study?
This clinical trial studies the following conditions: CTCL, PTCL.
What interventions are being tested in trial NCT03240211?
The interventions under investigation include: Pembrolizumab (DRUG), Decitabine (DRUG), Pralatrexate (DRUG).
Who is sponsoring clinical trial NCT03240211?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03240211 being conducted?
This trial has 2 study locations across Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CTCL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
COMPLETED · Phase 1
-
StrataCTX® as a Steroid Sparing Device
RECRUITING · NA
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
-
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.